JP2022526220A5 - - Google Patents
Info
- Publication number
- JP2022526220A5 JP2022526220A5 JP2021549368A JP2021549368A JP2022526220A5 JP 2022526220 A5 JP2022526220 A5 JP 2022526220A5 JP 2021549368 A JP2021549368 A JP 2021549368A JP 2021549368 A JP2021549368 A JP 2021549368A JP 2022526220 A5 JP2022526220 A5 JP 2022526220A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- hydrogen
- stereoisomer
- compound according
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201941013150 | 2019-04-01 | ||
| IN201941013150 | 2019-04-01 | ||
| PCT/IB2020/053038 WO2020202001A1 (en) | 2019-04-01 | 2020-03-31 | Substituted 5-cyclopropyl-1h-pyrazol-3-yl-amine derivatives as selective cdk12/13 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022526220A JP2022526220A (ja) | 2022-05-24 |
| JP2022526220A5 true JP2022526220A5 (enExample) | 2023-04-14 |
Family
ID=72666344
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021549368A Pending JP2022526220A (ja) | 2019-04-01 | 2020-03-31 | 選択的なｃｄｋ１２／１３阻害剤としての置換された５－シクロプロピル－１ｈ－ピラゾール－３－イル－アミン誘導体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230212142A9 (enExample) |
| EP (1) | EP3946288A4 (enExample) |
| JP (1) | JP2022526220A (enExample) |
| CN (1) | CN113727707A (enExample) |
| AU (1) | AU2020251843A1 (enExample) |
| CA (1) | CA3135563A1 (enExample) |
| WO (1) | WO2020202001A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022084930A2 (en) * | 2020-10-22 | 2022-04-28 | Aurigene Discovery Technologies Limited | Cancer therapy using a combination of cdk7 inhibitor with an anti-microtubule agent |
| CN112979567B (zh) * | 2021-03-05 | 2023-07-18 | 中国医科大学 | Cdk12小分子抑制剂的化合物及其应用 |
| TW202327583A (zh) * | 2021-12-06 | 2023-07-16 | 美商艾克塞里克斯公司 | 使用ｃｄｋ７抑制劑治療癌症之方法 |
| US12084453B2 (en) | 2021-12-10 | 2024-09-10 | Incyte Corporation | Bicyclic amines as CDK12 inhibitors |
| JP2025526266A (ja) * | 2022-07-05 | 2025-08-13 | オーリジーン オンコロジー リミテッド | Ｃｄｋ１２／１３阻害剤としての置換ｎ－（ピリジン－２－イル）アセトアミド誘導体 |
| WO2024140653A1 (zh) * | 2022-12-27 | 2024-07-04 | 南京圣和药业股份有限公司 | 选择性cdk12/13抑制剂及其应用 |
| CN118130793B (zh) * | 2024-02-26 | 2025-07-29 | 赣南医科大学 | 视网膜母细胞瘤的生物标志物cdk12及其应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006070198A1 (en) * | 2004-12-30 | 2006-07-06 | Astex Therapeutics Limited | Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases |
| MX2007008008A (es) * | 2004-12-30 | 2007-11-12 | Astex Therapeutics Ltd | Compuestos de pirazol que modulan la actividad de las cinasas cdk, gsk y aurora. |
| SI3302448T1 (sl) * | 2015-06-04 | 2024-03-29 | Aurigene Oncology Limited | Substituirani heterociklični derivati kot inhibitorji cdk |
-
2020
- 2020-03-31 CN CN202080026783.4A patent/CN113727707A/zh active Pending
- 2020-03-31 WO PCT/IB2020/053038 patent/WO2020202001A1/en not_active Ceased
- 2020-03-31 JP JP2021549368A patent/JP2022526220A/ja active Pending
- 2020-03-31 CA CA3135563A patent/CA3135563A1/en active Pending
- 2020-03-31 US US17/600,024 patent/US20230212142A9/en not_active Abandoned
- 2020-03-31 EP EP20784690.8A patent/EP3946288A4/en not_active Withdrawn
- 2020-03-31 AU AU2020251843A patent/AU2020251843A1/en not_active Abandoned